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Abstract.  We have previously identified a  130-kD  cell 
surface protein that is involved in calcium uptake and 
skeleton formation by gastrula stage embryos of the 
sea urchin Strongylocentrotus purpuratus  (Carson et 
al.,  1985. Cell.  41:639-648).  A monoclonal antibody 
designated rnAb  1223 specifically recognizes the 130- 
kD protein and inhibits Ca  ÷~ uptake and growth of the 
CaCO3 spicules produced by embryonic primary 
mesenchyme cells cultured in vitro. In this report, we 
demonstrate that the epitope recognized by mAb 1223 
is located on an anionic, asparagine-linked oligosac- 
charide chain on the 130-kD  protein. Combined enzy- 
matic and chemical treatments indicate that the 1223 
oligosaccharide contains fucose and sialic acid that is 
likely to be O-acetylated. Moreover, we show that the 
oligosaccharide chain containing the 1223 epitope spe- 
cifically binds divalent cations, including Ca  +2. We 
propose that one function of this negatively charged 
oligosaccharide moiety on the surfaces of primary 
mesenchyme cells is to facilitate binding and seques- 
tration of Ca  +: ions from the blastocoelic fluid before 
internalization and subsequent deposition into the 
growing CaCO3 skeleton. 
FUNDAMENTAL  problem in cellular biology is to under- 
stand the means by which certain cells in multicellu- 
lar organisms differentiate to a state in which they are 
capable of laying down mineralized tissues. To achieve this 
differentiated state, precursor  cells must acquire the ability 
to select appropriate ions from the surrounding fluid and or- 
ganize these ions into a crystalline or semicrystalline form. 
Sea urchin embryos provide a useful system in which to study 
the developmental process of biomineralization.  Of particu- 
lar interest is the mechanism by which the fifty or so primary 
mesenchyme cells  (PMCs) t of the gastrula  stage embryo 
acquire the ability to sequester Ca  ÷2 ions and build the em- 
bryonic  CaCO~ skeleton.  Using  a  monoclonal  antibody, 
mAb 1223, a 130-kD cell surface protein has been identified 
that plays an essential role in Ca  ÷2 uptake by PMCs (Carson 
et al.,  1985). This antibody has been shown to selectively 
interfere with the uptake process rather than with the sub- 
sequent phase during which ionic calcium is converted to 
crystalline CaCO3 (Grant et al., 1985). Recent studies have 
shown that the 130-kD protein is specifically expressed on 
the surface of the PMC at the time that the cells begin to ac- 
cumulate calcium (Farach et al., 1987). At this stage of de- 
velopment, no other cell types within the embryo synthesize 
or express significant amounts of this antigen. 
A number of laboratories have reported the development 
1. Abbreviations  used in this paper: Endo, endoglycosidase; PNGase, pep- 
tide: N-glycosidase; PMC, primary  mesenchyme cells. 
of antibody  probes  that  recognize  PMC-specific  antigens 
similar to the 130-kD protein recognized by mAb 1223. leaf 
et al. (1987) recently identified a 130-kD protein encoded by 
a PMC-specific cDNA clone. Polyclonal antibodies directed 
against a portion of this sequence expressed as a fusion pro- 
tein with/3-galactosidase were prepared. This research group 
also has isolated a monoclonal antibody, mAb B2C2, which 
apparently recognizes the same 130-kD protein that is recog- 
nized both by their fusion protein polyclonal antibody and by 
mAb 1223 (Anstrom et al., 1987). However, neither of  these 
antibodies is able to inhibit calcium uptake by cultured PMCs 
(Farach-Carson,  unpublished  observations).  At  least  two 
other groups also have described  the use of PMC-specific 
probes that recognize proteins that may be antigenically re- 
lated to the  130-kD protein  recognized by mAb  1223. We 
have tested the antibody designated 1G8 (Wessel et al., 1984) 
and found that it, like B2C2, does not inhibit calcium influx 
into PMCs (Farach-Carson and Wessel, unpublished obser- 
vations). Shimizu et al. (1988) recently described yet another 
PMC-specific monoclonal called P4 that recognizes a series 
of proteins including one with an apparent molecular mass 
of 130 kD. The functional effects of  this antibody on calcium 
uptake have not been investigated. 
The  unique  ability  of mAb  1223 to  inhibit  biological 
processes  as  complex  as  calcium  uptake  and  embryonic 
skeleton formation led us to investigate the nature of the epi- 
tope on the 130-kD protein recognized by mAb 1223. In this 
report,  we present evidence that the 130-kD protein recog- 
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bryos is a Ca  +2 binding glycoprotein. Furthermore,  we find 
that the epitope recognized by mAb 1223 is contained within 
a 3,200 M~ complex-type asparagine-linked oligosacchaxide 
that is attached to the  130-kD glycoprotein on PMCs.  The 
pronase-derived glycopeptide beaxing the  1223 antigen ex- 
hibits a net negative charge at neutral pH. Chemical and en- 
zymatic treatments that selectively destroy particular oligo- 
saccharide  structures  indicate  that  substituted  sialic  acid 
residues comprise an essential part of the 1223 epitope. Fur- 
thermore, we find that the isolated pronase glycopeptide con- 
raining the  1223 epitope specifically binds divalent cations 
including Ca  +2. The unique properties of the oligosaccharide 
epitope recognized by mAb 1223 may account for the func- 
tional effect seen on skeleton formation in cultured spicule- 
forming cells. 
Materials and Methods 
Materials 
All materials used for polyacrylamide gel electrophoresis were purchased 
from  Bio-Rad  Laboratories  (Richmond,  CA).  Nitrocellulose was  from 
Schleicher & Schueli, Inc. (Keene, NH). Nal25I (carrier free), [3H]leucinc 
(45  Ci/mmol) and 45CaCi2 (10-40 mCi/mg) were obtained from Amer- 
sham Corp. (Arlington Heights, IL). 35SO4 (carrier free) and [6-3H]glu  - 
cosamine (40 Ci/nunoi) were purchased from ICN Biomedicals Inc. (It- 
vine, CA). The Vectastain ABC (anti-mouse) kit for peroxidase staining of 
immunoblots was from Vector Laboratories, Inc. (Burlingame, CA). Tissue 
culture media and  fetal calf serum were from Hazelton Biologics, Inc. 
(Lenexa, KS). Horse serum was purchased from Gibco Laboratories (Grand 
Island,  NY).  Tunicamycin, all detergents, and enzymes were purchased 
from Boehringer Mannheim Biochemicals (Indianapolis, IN) with the ex- 
ception of chondroitinase ABC and keratanase that were obtained from 
Miles Scientific Die. (Naperville, IL) and neuraminidases that were from 
Calbiochem-Behring Corp. (San Diego, CA). Normal mouse IgG was from 
Pel-l:reez Biologicals (Rogers, AR). Anti-mouse IgG (goat) and the immu- 
noglobulin subisotyping kit were purchased from HyClone Laboratories 
(Logan, UT). Proteins (fetuin, hemoglobin, BSA, cytochrome c) as well as 
all chromatography resins were purchased from Sigma Chemical Co. (St. 
Louis, MO). Purified calmodulin was a gift of Dr. A. Means and Endo N 
was generously provided by Dr. E  Troy. The monoclonal antibody B2C2 
and the fusion polyelonal were provided by Dr. R. Raft. All other chemicals 
used were reagent grade or better. 
Culture of Sea Urchin Embryos and Primary 
Mesenchyme Cells 
Sea urchins were purchased from Pacific Bio Marine Laboratories Inc. 
(Venice, CA). Gametes were harvested and embryos cultured in artificial 
sea water at 14°C as described (Heifetz and Lennarz, 1979).  Developmental 
stages were defined according to the criteria set forth by Galileo and Morrill 
(1985).  Primary mesenchyme cells were isolated and cultured in vitro as 
described (Carson et al., 1985).  In certain experiments, PMCs were treated 
with tunicamycin on the second day after plating. Tunicamycin (0.1 ~tg/ml) 
was added from a sterile stock solution prepared in DMSO. Control cultures 
received DMSO alone.  Protein synthesis was monitored in tunicamycin- 
treated cells by  labeling cells with  [3H]leucine as described previously 
(Farach et al., 1987).  Radioactivity incorporated into macromolecular ma- 
terial was assessed after TCA precipitation as described (Farach et al., 
1988). 
Preparation of  Labeled Embryo Extracts 
Gastrula stage embryos were labeled with [3H]leucine or [3H]glucosaminc 
(250 p.Ci/ml) as described (Carson et al.,  1985),  except that labeling with 
glucosamine was extended to 6  h.  The embryos were then washed with 
artificial sea water and solubilized overnight in a Tris-buffered solution con- 
taining 2% (wt/vol) cholate. The insoluble material was removed by cen- 
trifugation for 5 rain in a microfuge (Beckman Instruments Inc., Palo Alto, 
CA). The soluble fraction was chromatographed on a  1.5  x  26-cm Sepha- 
dex G-50 column eluted with 10 mM sodium acetate, pH 7.0, 5% (vol/vol) 
ethanol and 0.02%  (wt/vol) NAN3. All labeled material eluting in the void 
volume was combined and concentrated by lyophilization. This fraction is 
termed the "macromolecular fraction" throughout this text. 
Monoclonai  Antibody 1223 
Hybridoma 1223 was cultured in Iscoves medium supplemented with 10% 
FCS as previously described (Carson et al., 1985).  mAb 1223 was purified 
from conditioned medium by passage over Protein A Sepharose. Subclass 
identification has demonstrated that mAb 1223 is an IgGl. Immunoaflinity 
beads were prepared by coupling mAb 1223 or preimmune mouse IgG to 
cyanogen bromide-activated Sepharose 4B (Carson et al.,  1985). 
lmmunoblotting 
Immunoblots were performed with  125I-labeled second antibody as de- 
scribed previously (Farach et al.,  1987) except that all blotting steps were 
performed using an Omniblot apparatus (ABN, Emeryvilfe, CA). The blots 
were dried and analyzed by autoradiography. Radioactive spots were quanti- 
tated by direct scanning of the radiograms using a transmittance/reflectance 
scanning densitometer (GS-300; Hoefer Scientific Instruments, San Fran- 
cisco, CA) equipped with a data software system (GS-350; Hcefer Scientific 
Instruments). For rapid detection of immunoreactive material when quanti- 
ration was unnecessary (such as screening column fractions), a peroxidase 
assay system was employed. In this case, samples were dot blotted onto a 
nitrocellulose filter using a 96-well apparatus (Bio-Rad Laboratories). The 
filter was blocked for 30 rain with a  solution containing 0.05%  (vol/vol) 
Tween 20 in PBS, pH 7.5. At the end of the blocking period, this solution 
was aspirated and replaced with 5/tg/ml ofmAb 1223 in a fresh Tween-PBS 
solution. Incubation with first antibody was continued for a minimum of 4 h, 
but was usually overnight. At the end of  the incubation period, the filter was 
washed 4-5 times in PBS without Twcen 20 and immediately developed 
upon the addition f 4-chloro-l-napthol and H202.  Development was stopped 
by replacing this solution with water.  Blots developed in this manner were 
immediately photographed. 
Sample Preparation and Analysis 
Gastrula-stage embryos were collected using a hand driven centrifuge and 
washed twice with freshly filtered artificial sea water.  Embryo pellets were 
either used immediately or stored at -70°C until use. Embr~s were rou- 
tinely solubilized overnight at 4°C in a buffer consisting of 2% (wt/vol) Na 
cholate in 10 mM Tris-HCl, pH 8.0, and a battery of protease inhibitors (Car- 
son et al.,  1985).  In other cases, PMCs were scraped from tissue culture 
plates,  washed in artificial sea water and then solubilized in this same 
buffered detergent solution.  Protease inhibitors were omitted only when 
pronase digestion was to be employed in subsequent steps of the protocol. 
Pronase digestions using predigested pronase were carried out for 48 h 
at 50°C as described by Hart and Lennarz (1978). Samples were diluted ap- 
proximately twofold during the entire procedure.  Glycosidase digestions 
were performed in all cases exactly according to the manufacturer's speci- 
fications. The details are included in the figure legends where applicable. 
Enzyme digestions were routinely performed on samples containing 100 #g 
of solubilized protein. Protease inhibitors were present during all glycosi- 
dase digestions. Internal standards were included in a parallel sample to in- 
sure that the individual enzymes were active in the solubitization buffer. 
Isolation of the 1223 Pronase Glycopeptide 
Embryos were extracted in solubilization buffer and digested with pronase 
as described above. At the end of the digestion, any insoluble material was 
removed by low speed centrifugetion and the soluble fraction was passaged 
over Sepharose 4B beads to which either mAb 1223 or preimmunc mouse 
IgG was coupled as described (Carson et al.,  1985).  Bound material was 
elnted from each column with 6 M guanidinc HCI and placed into dialysis 
to remove the chaotrope. The two fractions are henceforth referred to as 
"1223  glycopeptide" and "preimmunc glycopeptide control." 
Ion Exchange Chromatography 
The column used for analysis of the behavior of all preparations during an- 
ion exchange was a 3-ml column of DE 52. The starting buffer consisted 
of IO mM sodium phosphate, pH 7.2.  Samples were adjusted to the running 
buffer by dialysis before application to the column. Samples were eluted 
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dient from 0 to 0.5 M NaCI, and then with 5 ml of 0.5 M NaCI. Aliquots 
(200 #1) of 1.0 ml column fractions routinely were dot blotted onto nitrocel- 
lulose and antibody-binding fractions were identified from immunobinding 
blots as described above. Salt concentrations were measured from conduc- 
tivities determined using a CDM 83 conductivity meter (Radiometer, Co- 
penhagen, Denmark). 
Gel Permeation Chromatography 
Samples were analyzed by molecular exclusion on a 1.5 x  45 cm column 
of Sephadex G-75 (superfine). The running  buffer for this column consisted 
of PBS either with or without 1.0 mM EDTA depending upon the experi- 
ment. The column was calibrated with a series of protein and saccharide 
molecular mass markers. On some occasions, the samples were dialyzed 
versus 10 mM EDTA before application to this column. Aliquots (10-20% 
of  the total volume) of the column  fractions were dot blotted onto nitrocellu- 
lose, probed with mAh 1223, and the antibody-binding fractions identified. 
Calcium Binding Assays 
Two complementary assays were employed to test the ability of various 
preparations to bind Ca  +2. 
Nitrocellulose Assay. The procedure we used was modified from that of 
Maruyama et al., (1984). The sample(s) to be tested was dot blotted onto 
a piece of nitrocellulose that was then soaked for 20 min in a solution con- 
sisting of 60 mM KCI, 5 mM MgCIz and 10 mM Bicine, pH 6.8. The solu- 
tion was changed three times and incubated each time for 20 min with this 
buffer, following which 45CaCI2 was added at a final concentration of 0.5 
#Ci/ml. After I h, the filter was washed three times with 50 ml of deionized 
water for 10 min/wash, then dried,  and autoradiogmphed.  2 
Gel Filtration Assay. Ca  +2 binding to soluble fractions was monitored 
using a modification of the gel filtration method originally described by 
Hummel and Dreyer (1962). A Sephadex G-10  column (1  x  27 cm) was 
equilibrated with various concentrations of 45CaC12 in a  running buffer 
consisting of 10 mM Tris-HCI containing 0.15 M NaCI and 5 mM KCi. The 
effluent solution was collected in 1.0 ml fractions, and the baseline radioac- 
tivity levels were determined by counting 25-#1 aliquots from each fraction 
in a scintillation counter. Samples to be tested for calcium binding ability 
were applied to the column and the shape of the elution profile determined 
by counting the column  fractions. These profiles reflect the association-dis- 
association phenomenon occurring between the applied sample and the free 
calcium in the running buffer and give a characteristic "peak and trough" 
when binding occurs (Ackers and Thompson,  1965). 
Other Procedures 
Protein concentrations were determined using the method of Lowry et al., 
(1951) using BSA as a standard. SDS-PAGE  was performed on 8.75% poly- 
acrylamide gels as described previously (Carson et al., 1985). Hydrazinoly- 
sis  and reacetylation  were  performed  using  the  standard  procedure  of 
Takasaki et al. (1982). Fetuin glycopeptides to be used as standards for gel 
filtration were prepared as described by Spiro and Bhoyroo (1974). 
Results 
The 1223 Epitope Is An Oligosaccharide 
In preliminary experiments, we were unable to immunopre- 
cipitate  the  1223  antigen-bearing protein  from  [35S]meth- 
ionine-labeled products  prepared  by  translating RNA  iso- 
lated  from  PMC  cultures.  This  suggested  that  part  of the 
epitope might be a  product of posttranslational processing. 
We therefore  tested the ability of a  series of proteases  and 
glycosidases of varying specificity to degrade the 1223 anti- 
gen.  Preliminary experiments showed that the epitope was 
2. Since the completion of the majority of this work, we have found that 
Zeta-Probe (Bio-Rad Laboratories) provides a much improved matrix on 
which  to  perform  overlays with  45Ca+2. Not  only does  the  negatively 
charged  1223 glycopeptide bind more efficiently to this cationized nylon 
membrane, but also the background is consistently reduced with shorter 
wash times. 
not destroyed by either treatment with pronase (see below) 
or by hydrazinolysis and subsequent reacetylation (not shown). 
In contrast, treatment with various glycosidases (see below) 
disrupted antigen-antibody binding to differing extents.  In 
light of these preliminary results, further experiments were 
undertaken to characterize the oligosaccharide epitope rec- 
ognized by mAb  1223. 
Previous studies have shown that although the 130-kD gly- 
coprotein is a  major protein synthesized de novo in gastrula 
stage sea urchin embryos, it is a  minor protein in total em- 
bryonic extracts  (Farach  et  al.,  1987).  We  therefore  used 
Western blotting to take advantage of the high affinity of mAb 
1223 for the 130-kD protein as a means of detecting the anti- 
gen  in embryo  extracts  after  various  test  endoglycosidase 
treatments.  In Fig.  1  is  shown the results of blotting with 
mAb  1223  after  treatment with  either  Endoglycosidase  F 
Figure I. Effect of endoglycosidases on the 1223 antigen. Gastrnla 
stage embryos were  solubilized in a  solution containing 10 mM 
Tris-HCl, pH 8.0, 2% sodium cholate and a battery of protease in- 
hibitors. Insoluble material was removed by low speed centrifuga- 
tion. The material remaining in the supernatant is referred to as the 
"gastrnla extract:in this experiment,  100-/zg aliquots of the gas- 
trula extract were treated under denaturing conditions with the en- 
doglycosidases Endo F  (1.9 mU) and PNGase F  (2.0 mU) before 
Western blot analysis with mAb 1223 and iodinated second anti- 
body. Autoradiography was for 4 h at -70°C. The conditions for the 
deglycosylation reactions were as follows: total gastrula extracts 
were dialyzed against 10 mM Tris-HCl, pH 8.0, containing 0.01% 
sodium cholate and 0.02 % NAN3. For PNGase F treatment, sam- 
ples were heat denatured in 0.5 % (wt/vol) SDS and 1%/$-mercapto- 
ethanol and then diluted to 0.1% (wt/vol) SDS in a solution contain- 
ing (final concentrations)  0.1 M Na phosphate buffer, pH 8.6, 0.02 M 
Na EDTA, and 0.6% (wt/vol) BIGCHAP. Incubation  with PNGase 
was overnight at room temperature. Parallel deglycosylation reac- 
tions were performed with immunoglobulin G  and ovalbumin as 
substrates. The protocol used for Endo F was the same except that 
a 0.05 M (final concentration) Na acetate buffer, pH 5.0, was used 
in place of the phosphate-EDTA buffer. As shown above, treatment 
with PNGase removes the immunoreactive portion of the 130-kD 
glycoprotein. No effect of PNGase F was seen under nondenaturing 
conditions. 
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the 130-kD glycoprotein. Primary mesenchyme cells were cultured 
as described  in Materials  and Methods.  On the second day after 
plating, tunicamycin (0.1 t~g/rnl) was added from a sterile stock so- 
lution prepared in DMSO. Control cultures received DMSO alone. 
On day 3, PMCs were scraped from the plates, solubilized as de- 
scribed in Fig. 1 and analyzed by Western blotting using mAb 1223 
and iodinated second antibody. Aatoradiography  was carried  out 
overnight. Lanes a  and b, duplicate control cultures;  lanes c and 
d, duplicate cultures receiving 0.1 tzg/ml tunicamycin. 
(Endo F) or peptide: N-glycosidase (PNGase F). As seen in 
the autoradiograms, treatment with PNGase but not Endo F 
selectively removed the portion of the molecule containing 
the  mAb  1223  binding  site.  Additional  experiments  also 
demonstrated that treatment with Endo H  had no effect on 
the ability of mAb 1223 to recognize the  130-kD glycopro- 
tein  (data  not  shown).  Consistent  with  these  results,  we 
found  that  PNGase digestion  of the  130-kD  glycoprotein 
metabolically labeled with [3H]leucine destroyed the ability 
of the 130-kD polypeptide to bind to an immunoaffinity col- 
umn prepared by coupling rnAb  1223 to Sepharose 4B. 
The release of the 1223 epitope by PNGase F led us to in- 
vestigate whether tunicamycin treatment,  which  interferes 
selectively with assembly of N-linked chains on core pro- 
teins, would decrease the immunoreactivity of the  130-kD 
glycoprotein.  Cultures  of PMCs  were prepared from dis- 
sociated  embryos.  Previous  studies  (Farach  et  al.,  1987) 
have shown that on the second day after plating the synthesis 
of the 1223 epitope-bearing glycoprotein by PMCs increases 
dramatically. Consequently, we examined the effect of tuni- 
camycin on assembly of  the 1223 glycoprotein by PMCs dur- 
ing day 2 in culture. As shown in Fig. 2, cultures receiving 
0.1 t~g/ml of tunicamycin contained considerably less immu- 
noreactive  130-kD glycoprotein than did control cultures. 
Quantitative densitometry showed that mAb 1.223 binding in 
the experiment shown in Fig. 2 was reduced by 64 %. To as- 
sess the effects of tunicamycin treatment on overall protein 
synthesis by PMCs, parallel cultures were incubated with 20 
~Ci/ml pH]leucine throughout the experimental course de- 
scribed in the legend to Fig.  2.  Radioactivity incorporated 
into macromolecular material was then determined in TCA 
precipitates. Little if any effect of tunieamycin was observed 
at 0.1  #g/ml, although higher doses (0.5-1.0 ~g/ml) did in- 
hibit leucine incorporation by 20-30%. These findings, cou- 
pled with the sensitivity to PNGase F, provide strong sup- 
porting evidence that the oligosaccharide chain containing 
the epitope recognized by mAb 1223  is part of a complex- 
type oligosaccharide chain that is linked to the core protein 
via an asparagine residue. 
Assay of Glycopeptides 
To further characterize the structural and functional proper- 
ties of the oligosaccharide chain containing the 1223 antigen, 
we first prepared pronase glycopeptides from gastrula stage 
embryos or cultured PMCs. These glycopeptides then were 
dot blotted onto a piece of nitrocellulose and assayed for bind- 
ing with mAb 1223 as described in Materials and Methods. 
Although there are limitations to this assay system (see be- 
low),  it nonetheless enabled us to characterize a  quantita- 
tively minor antigen that could only be followed by binding 
of our monoclonal antibody. As indicated above, the epitope 
recognized by 1223 was resistant to treatment with pronase, 
although  the efficiency of binding  of mAb  1223  was only 
10-15%  control  after  protease digestion.  Control  experi- 
ments were required to determine whether the observed loss 
in binding efficiency was because of a loss in antigenicity or 
to  a  loss  in  efficiency of binding  of the  1223  antigen  to 
nitrocellulose after pronase treatment. To test this, gastrula 
stage  embryos  were  labeled  with  either  [3H]leucine  or 
[3H]glucosamine and the efficiency of binding to nitrocellu- 
lose measured for these two preparations either before or af- 
ter pronase digestion. As shown in Table I, we found that the 
efficiency of binding of the total pool of glucosamine-labeled 
pronase glycopeptides was only 10%, which correlated with 
the signal reduction we saw with mAb 1223  binding. From 
this,  we concluded  that if mAb  1223  recognized a  typical 
pronase glycopeptide from gastrula stage embryos, the  10- 
15 % binding activity that was retained after pronase diges- 
tion was about the maximum expected. 
Table I. Binding of Various Metabolically Labeled 
Macromolecular  Fractions, to Nitrocellulose 
Radiolabel  Treatment*  % Bound§ 
[3H]Leucine  None  78 +  12 
[3H]Leucine  Pronase  2  5:0.5 
[3H]Glucosamine  None  53 5:8 
[3HlGlucosamine  Pronase  10 5:3 
* Gastrnla stage embryos were labeled for 2 h (lcu) or 6 h (gin) with ~H 
precursors and the macromolecular  fraction isolated as described in Materials 
and Methods. 20,000 cpm of labeled material was used per well in all assays. 
~: Macromolecular  fractions were either treated with pronase  as described in 
Materials and Methods or incubated in parallel in the absence  of enzyme. 
§ Nitrocellulose  was 0.45 ~m pore size. Wash steps using Tween-20 in PBS 
were as described in Materials and Methods. 
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Figure 3. Behavior of the 1223 antigen-bearing pronase glycopep- 
tide on Sephadex G-75. The 1223 glycopeptide was prepared as de- 
scribed in Materials and Methods. The behavior of  the glycopeptide 
during gel permeation chromatography was assessed using a Sepha- 
dex G-75 column as described  in the text. The elution position of 
the glycopeptide bearing the 1223 epitope was monitored using a 
nitrocellulose assay and an immunobinding dot blot protocol as de- 
scribed in Materials and Methods. Quantitation of dot intensity was 
performed using a densitometer. The elution position of the  1223 
glycopeptide was found to be calcium dependent. Samples prepared 
in the presence of calcium (which is used during the pronase diges- 
tion) and run directly on the column using PBS as the running buffer 
elute in a broad peak beginning at the void volume of the column 
(A -  A). Dialysis of the sample versus EDTA before application to 
the column results in conversion to a lower molecular mass form 
(A--A). The molecular mass markers are as follows: (a) hemoglo- 
bin;  (b) 9 kD dextran;  (c) 3.5  kD fetuin glycopeptide;  (d) cyto- 
chrome c; (e) 1.5 kD fetuin glycopeptide; and (f) oxytocin.  The 
Vo and V~ markers were blue dextran and potassium dichromate, 
respectively. 
Sizing of the 1223 Epitope-bearing Pronase 
Glycopeptide 
The 1223 pronase glycopeptide was prepared as described 
in Materials and Methods. The size of the glycopeptide was 
assessed by comparison of its elution position on Sephadex 
G-75 compared to a series of polypeptide and glycopeptide 
standards. As shown in Fig. 3 and Table II, the elution posi- 
tion of the  1223  epitope-bearing pronase glycopeptide was 
found to be dependent upon the presence of divalent cations. 
In the presence of divalent cations  the  1223  glycopeptide 
eluted as a broad peak beginning at the void volume of the 
column. When the sample was treated with EDTA before ap- 
plication to the column or when EDTA was added to the run- 
ning buffer, the 1223 glycopeptide was convened to a lower 
molecular mass form. Comparison of the elution position to 
that of a  series of standards indicates a molecular mass of 
'~3,200 D for the 1223 epitope-bearing pronase glycopeptide. 
This result led us to investigate the "aggregation-disaggrega- 
tion" of the 1223 glycopeptides in the presence and absence 
of various ions. 
In Table II, it can be seen that the aggregation of the 1223 
glycopeptide takes place in the presence of any of the divalent 
cations (Ca  +2,  Mg  +2, or Ba  +2) tested.  In contrast,  monova- 
lent cations, even at concentrations of 0.15 M, did not induce 
aggregation. Partial disaggregation could be achieved by the 
inclusion of 4 M urea in the sample. These results suggested 
that the isolated oligosaccharide was capable of binding diva- 
lent cations. One phenomenon repeatedly observed was that 
the intensity of the signal obtained in dot blots was dependent 
on the presence or absence of "aggregates" of the pronase 
glycopeptide. As illustrated in Fig. 3, the signal obtained by 
integrating the area under the peak for the lower molecular 
mass form was considerably reduced compared to the signal 
obtained when the sample was aggregated and eluted in the 
void volume. This cannot be explained by sample loss, be- 
cause the full intensity of the signal is recovered when cal- 
cium is added (not shown). These observations suggest that 
mAb 1223 binds better to the aggregated form of the antigen. 
The apparent size of the oligosaccharide released by PNG- 
ase treatment of the gastrula extract (as assessed by passage 
over G-75 and immunoblotting as above) was approximately 
the same as that of the pronase glycopeptide. This means that 
the size estimated for the pronase glycopeptide containing the 
1223 antigen is close to the size of the oligosaccharide chain 
and is not because of large amounts of a protease resistant 
core protein associated with the oligosaccharide chain. 
Ionic Character of the 1223 Epitope-Bearing 
Pronase Glycopeptide 
Ion exchange on DE 52 was chosen as the means of charac- 
terizing the charge characteristics of the 1223 glycopeptide. 
As shown in Fig.  4,  the pronase glycopeptide bearing the 
1223  epitope bound to DE 52 at neutral pH and was eluted 
with a salt concentration between 0.2 and 0.3 M NaCI. This 
negative charge character is consistent with its ability to ag- 
gregate in the presence of divalent cations. A small amount 
of the  antibody-binding activity consistently  eluted  at the 
start of the salt gradient; in the experiment shown in Fig. 4, 
this represented  15 % of the total. 
The 1223 Giycopeptide Binds Calcium 
Two separate assays were devised to detect direct binding of 
calcium to the pronase glycopeptide containing the 1223 epi- 
tope.  Such binding would account for the tendency of the 
3,200 Mr glycopeptide to aggregate in the presence of diva- 
lent  cations  (see  above).  In  preliminary  experiments,  we 
Table II. Aggregation-Disaggregation  of  the 1223 
Glycopeptide Induced by Divalent Cations 
Elution 
Treatment conditions  position on G-75 
Pronase digest  Vo 
Pronase digest dialyzed versus 
10 mM EDTA 
Add either Ca  +2, Mg  +2 or Ba  +2 to 
sample 2* 
Add Na  + or K  + to sample 2* 
Pronase digest plus 4 M urea 
M,  =  3,200 
Vo 
Mf  =  3,200 
75% Vo 
25 % Mr =  3,200 
* Divalent cations were added back to the pooled, dialyzed, EDTA-treated 
pronase glycopeptide eluting from the G-75 column at a position indicating a 
molecular mass of 3.2 kD. The concentration of divalent cation was 1.0 mM 
in all cases. The samples were then rerun over the G-75 column as described 
in Materials and Methods. 
¢ Monovalent ions (Na+ and K+) were present at concentrations of 0.150 M 
and 5  raM,  respectively. 
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Figure 4. Behavior of the 1223-antigen bearing pronase glycopep- 
tide during anion exchange. The pronase glycopeptide containing 
the 1223 epitope was prepared from gastrula stage embryos as de- 
scribed in the text. All samples were adjusted to the running buffer 
by dialysis before application to the column. The column used was 
a 3-ml column of DE 52 with a running buffer of 10 mM sodium 
phosphate, pH 7.2. Samples were eluted as described in Materials 
and Methods. Aliquots of the fractions were dot blotted onto nitro- 
cellulose at the end of the run and antibody binding fractions iden- 
tiffed and quantitated from immunobinding blots.  The bar graph 
represents  the  intensity  of the  signal  obtained  densitometrically 
across the column fractions. Conductivities were read using a con- 
ductivity meter (o- o). 
More precise analysis of the binding constant must await iso- 
lation of larger amounts of material than is presently available. 
Immunoblotting of the 1223 Glycopeptide 
after Chemical Treatment or Treatment with 
Various Glycosidases 
To identify structural features of the oligosaccharide bearing 
the 1223 epitope, we selectively modified various saccharide 
moieties and then assayed for retention or loss of reactivity 
with mAb 1223.  As shown in Table III, most treatments, in- 
cluding various glycosidases and phosphatases, had no effect 
on immunoreactivity of the 1223 antigen with mAb 1223. In- 
terestingly, Ot-L-fucosidase  digestion increased binding from 
3-10-fold  in  duplicate  experiments  (also  see  below,  Fig. 
8).  In contrast, treatment with neuraminidase from several 
sources reduced binding by only 10-40%. The epitope was 
found to be quite stable to base, but was easily destroyed by 
mild acid hydrolysis. 
As mentioned above, the  signal  on  immunoblots corre- 
sponding to the 1223 epitope was reduced, but not destroyed, 
found that we could not isolate sufficient amounts of purified 
material to perform Scatchard analysis from equilibrium di- 
alysis or centrifugation assays. Therefore, the assay systems 
used to measure 4sCa÷2 binding  were chosen because they 
could detect calcium binding even with the extremely small 
amount of the 1223 glycopeptide that we were able to isolate. 
As seen in Fig. 5 A, the 1223 glycopeptide, but not a preim- 
mune glycopeptide control  (see  Materials  and  Methods), 
binds 4sCa+2 in a nitrocellulose overlay assay. Although not 
shown in this figure, we found that the bound calcium could 
not be displaced from the 1223 glycopeptide bound to nitro- 
cellulose by overnight incubation in PBS containing 5 mM 
K ÷ and 0.15  Na  ÷, although  it could be readily removed by 
the addition of 10 mM EDTA to the wash solution. From this, 
we suspected that the binding affinity of Ca  +2 to the  1223 
glycopeptide was relatively high. This was tested more directly 
using a gel filtration assay on Sephadex G-10 as described in 
Materials  and  Methods.  As  shown  in  Fig.  5  B,  when the 
column  was equilibrated  with 45Ca  +2 before application of 
the  1223  glycopeptide preparation, a  peak of radioactivity 
was observed in the void volume. This peak resulted from 
the association of free ionic calcium in the running buffer 
with the much larger 1223 glycopeptide. The lowest concen- 
tration of calcium at which binding could be detected using 
this assay was 10  -7 M. Neither the preimmune glycopeptide 
control nor the •3.5  kD pronase glycopeptide of fetuin bound 
calcium during  passage through the column.  Calmodulin, 
(25 #g/run) which was used as a positive control in this assay, 
also began to bind calcium in this assay at 10  -7 M. This be- 
havior is consistent with its reported binding constant (2  x 
l0  s M-') for calcium (Ogawa and Tanokura,  1984).  Because 
of the similar calcium-binding behavior they displayed in this 
assay, it appeared that the association constant of the  1223 
glycopeptide for calcium is  similar to that of calmodulin. 
Figure 5. The 1223 antigen-bearing pronase glycopeptide binds cal- 
cium.  A shows the autoradiogram obtained from a 45Ca+2 overlay 
of the immunoaflinity-purified  1223 glycopeptide blotted onto ni- 
trocellulose. 4SCa  +2 selectively binds to the 1223 glycopeptide but 
not to a control prepared  using immunoaflinity beads coupled to 
preimmune mouse IgG. The isolated samples used in these experi- 
ments were prepared from 2 ml of packed sea urchin embryos that 
had been solubilized and digested with pronase as described in the 
text. The first well contains 10% of the 1223 glycopeptide prepara- 
tion and the succeeding wells represent serial dilutions. The amount 
of 1223 glycopeptide used was below the level of detection using 
either a microhexose or microLowry assay, but could readily be de- 
tected using an immunoassay with mAb 1223. B shows a gel permea- 
tion assay for calcium binding that was performed as described  in 
the  text.  The column  was equilibrated  with  10  -~ M 4sCa+2 and 
then loaded with the sample being tested for calcium binding. The 
resin (Sephadex G-10) was chosen such that the 1223 glycopeptide 
would elute in the void volume. (/,-z~) 1223 glycopeptide; (A-A) 
preimmune control; (.-  .) 3.5 kD fetuin glycopeptide prepared as 
described  in Materials and Methods.  Only the 1223 glycopeptide 
gives the peak and trough pattern  indicating calcium binding has 
taken place. 
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Treatment*  Immunobinding  Ca  +2 Binding 
Keratanase* (2 U/ml) (Pseudomonas) 
Chondroitinase ABC* (1 U/ml) (Proteus vulgaris) 
Alkaline phosphatase* (300 U/ml) (Escherichia coli) 
Acid phosphata~* (18 U/ml) (wheat germ) 
Neuraminidaset (0.1 U/ml) (Clostridium perfringens) 
(Arthrobacter ureafaciens) (Vibrio cholera) 
~-L-Fucosidase* (0.002 U/ml) (bovine epididymus) 
Mild acid hydrolysis~  (0.1 N TFA, 80  °,  1 h) 
~-EliminationQ (0.1 N NaOH, 37  °, 48 h) 
Mild base hydrolysis followed by neurarninidase (see 
text for details) 
Retained  NDII 
Retained  ND 
Retained  Retained 
Retained  ND 
MAb 1223 binding reduced 
by 10-40%  Retained 
MAb 1223 binding increased 
3-10-fold  Retained 
MAb 1223 binding destroyed  Retained 
Retained  Retained 
MAb 1223 binding destroyed  Retained 
* All treatments were performed according to the manufacturer's protocols. Parallel controls were always conducted to verify enzymic activity. 
~t Samples were analyzed by quantitation of autoradiographs from Western blots as described in Mau~rials and Methods. 
§ Samples were analyzed by quantitation of immunodot blots following neutralization of the samples. 
~ ND. 
after digestion with neuraminidase.  To assess whether this 
partial susceptibility to neuraminidase might be because of 
some unusual characteristics of a sialic acid-containing oli- 
gosaccharide bearing the 1223 epitope, we tested other agents 
that modify sialic acid structures. As shown in Fig. 6, Endo 
N,  which  specifically cleaves c~-2,8-polysialic  acid chains 
Figure 6. Digestion with Endo N 
reduces immunobinding of mAb 
1223 to the 130-kD protein. Gas- 
trula stage embryos were solubi- 
lized  as  described  in  Materials 
and Methods. Insoluble material 
was removed and the soluble frac- 
tion  was  treated  with  Endo  N, 
which selectively degrades c~-2,8- 
polysialic acid linkages. 100-Mg 
aliquots of total gastrula protein 
extracts  received  either  buffer 
alone (lane a) or 0.5 unit of Endo 
N (lane b). After incubation over- 
night at 25°C, the samples were 
separated  on  8.75% SDS-poly- 
acrylamide gels and analyzed for 
immunobinding to mAb 1223 on 
Western blots  using  J25I second 
antibody. The  reduction  of im- 
munobinding (estimated by den- 
sitometry) in this experiment was 
46%.  Also note the aggregation 
of the  130-kD glycoprotein seen 
in this experiment. This charac- 
teristic of the protein is discussed 
in the text. 
(Rutishauser et al.,  1985), also reduced but did not abolish 
immunoreactivity with mAb 1223.  A 50% signal reduction 
after digestion with Endo N  also was seen on dot blots of 
column fractions of control and Endo N-digested 1223 gly- 
copeptide passed over DE 52 (not shown). The elution posi- 
tion of the remaining immunoreactive material was not shifted, 
however, and eluted between 0.2 and 0.3 M NaCI as did the 
control. To obtain more information regarding the nature of 
the 1223 oligosaccharide, we turned to nonenzymatic treat- 
ments that might alter immunoreactivity more quantitatively. 
The 1223 epitope was found to be stable to mild periodate 
treatment (2 mM,  30 min, 0°C)  (see Fig.  7  a),  although 
harsher treatment (2 mM,  1 h, 25°C) partially abolished re- 
activity of the 130-kD glycoprotein with mAb 1223 (Brooks- 
Scott and  Lennarz,  unpublished  observations).  The  1223 
epitope also was stable to base (0.1 N NaOH, 37°C, 30 min 
to 24 h, in the presence or absence of 0.25 M NaBH4) (Fig. 
7, b  and c). Interestingly, however, the mAb  1223 epitope 
was completely lost when the 1223 glycopeptide was treated 
with mild base (0.1 M NaOH, 37°C, 30 min) and then digest- 
ed with  neuraminidase  from Clostridium perfringens  (see 
Fig. 7 d). This observation, coupled with the resistance to 
periodate, is consistent with the notion that sialic acid resi- 
dues on the  1223  glycopeptide might be substituted  with 
O-acetyl groups (Varki and Diaz, 1984). These substitutions 
would confer resistance to neuraminidase treatment unless 
these O-acetyl groups were removed by prior exposure to 
mild base (Schauer,  1987). The samples shown in Fig. 7, e 
andfwere both treated with acid (0.1 N HC1, 30 min, 100°C) 
before further analysis and were found to completely lose im- 
munoreactivity merely as a consequence of the acid hydroly- 
sis.  From these experiments, we concluded that the epitope 
recognized by mAb 1223 contains sialic acid which contains 
O-acetyl  side  chain  substitutions.  Since  de-O-acetylation 
does not affect antibody binding, it must be concluded that 
the base-labile substituent is not part of the epitope. 
As mentioned above, long-term (overnight, 25°C or 4  h, 
37°C)  treatment of the  1223  glycoprotein with  C~-L-fUCO- 
sidase increased the apparent binding of mAb  1223  to the 
glycoprotein by 3-10-fold. To demonstrate that this was a re- 
sult of the enzymatic activity of the fucosidase, we tested the 
time-dependence of the reaction. As shown in Fig. 8, fucosi- 
dase digestion produced an essentially linear increase in im- 
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the 1223 glycopeptide follow- 
ing  various  treatments.  Pro- 
nase glycopeptides were pre- 
pared  from  gastrula  stage 
embryos as described  in the 
text.  A  series  of  combined 
chemical and enzymatic treat- 
ments were then performed to 
determine which types of resi- 
dues were likely to constitute 
the  1223 epitope.  After  the 
initial treatment, samples were 
neutralized  and  sonicated  to 
disperse  the  precipitates  that 
formed  during  acid  or  base 
hydrolysis and/or heating. Enzymes were added where indicated to 
the resuspended,  neutral samples. The treated samples were then 
dot blotted onto nitrocellulose and analyzed for immunoreactivity 
with mAb 1223. The irregular  black spots on the filter represent 
'25I second antibody that was not washed from the filter, a techni- 
cal problem that was particularly  bad in this experiment because 
of the particulate nature of several of the samples after treatment. 
The treatments were as follows: (row a) 2 mM periodate,  30 min, 
0°C; (row b) 0.1 N NaOH, 24 h, 37°C; (row c) 0.1 N NaOH, 30 
min, 37°C; (row d) same as row c, then neutralized and treated with 
neuraminidase  (Clostridium perfringens), 0.1  U/ml,  4  h,  37°C; 
(row e) 0.1 N HC1, 30 min,  100°C; (row f) same as row e, then 
neutralized and treated with alkaline phosphatase; (row g) untreated 
pronase glycopeptides from gastrula  stage embryos. 
munoreactivity over a 3-h period. This finding suggests that 
the 1223 epitope-bearing oligosaccharide is heterogeneously 
fucosylated and that removal of the terminal fucose residues 
unmasks additional 1223 binding sites. Heterogeneous fuco- 
sylation does not explain the partial susceptibility previously 
seen to neuraminidase, since fucosidase treatment followed 
by neuraminidase digestion does not lead to complete loss of 
recognition by mAb 1223  (not shown). 
The Epitope Recognized by mAb 1223 and the 
Calcium Binding Site Are Distinct 
Because mAb 1223 inhibited calcium uptake into PMCs, we 
tested whether this could be attributed to inhibition of the as- 
sociation of calcium with the  1223  bearing pronase glyco- 
peptide. We consistently found no inhibition of calcium bind- 
ing to the 1223  glycopeptide or to the intact glycoprotein in 
the  nitrocellulose  45Ca  +2  overlay  assay  (data  not  shown). 
Concentrations of mAb 1223  up to 20 #g/ml, which is well 
over the saturation level (5 #g/ml) found to decrease calcium 
uptake into cells,  had  no effect on calcium binding  to the 
1223  glycopeptide. 
In vitro calcium binding overlays were also performed to 
test directly  whether  treatments  that  altered  immunoreac- 
tivity of mAb 1223  with the 1223  glycopeptide also altered 
Ca  ÷2 binding.  As shown in Table III, neither mild acid hy- 
drolysis nor treatment with  neuraminidase  destroyed Ca  ÷2 
binding to the  1223  glycopeptide. Likewise, mild base hy- 
drolysis followed by neuraminidase digestion (see above) did 
not eliminate Ca  ÷2 binding at pH 6.8. From these observa- 
tions,  we must conclude that removal of substituted  sialic 
acid from the 1223  glycopeptide destroys immunoreactivity 
without destroying Ca  ÷2 binding.  This must mean that the 
1223  epitope and the calcium binding  site occupy distinct 
sites on the 3,200 M, pronase glycopeptide. 
The Calcium Binding Properties of the 1223 
Glycopeptide A re pH Dependent 
To estimate the pK, of the residue(s) involved in Ca  ÷2 bind- 
ing to the  1223  glycopeptide, a  series of experiments was 
performed in which 45Ca÷2 binding was measured using the 
overlay procedure at varying pH values. We found that lower- 
ing the pH of the binding solution to 5.0 reduced binding by 
,,o50%. At pH 4.0, binding was barely detectable and at pH 
3.0 or below,  no binding  was detectable (data not shown). 
Binding was stable between pH 6.8 and 8.0. These observa- 
tions indicate that binding of Ca  +2 is dependent on pH and 
suggest that the active group has a  pKa value between 4.0 
and 5.0. 
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Figure 8. Time-dependent increase in immunoreactivity of  the 1223 
glycoprotein during digestion with C~-L-fucosidase.  A 3 mg/ml cho- 
late extract of gastrula stage embryos was prepared as described in 
Materials and Methods. At time zero, 0.002 U/ml of C~-L-fucosidase 
was added and 40 #1 aliquots removed from the mixture at various 
time intervals.  Proteins  in the  aliquots  were  separated  by SDS- 
PAGE, and the immunoreactivity with mAb 1223 assayed by West- 
ern blotting with an iodinated second antibody as described in the 
text. The intensity of the band in the autorad at 130-kD was mea- 
sured  densitometrically  and  plotted.  (a-a)  Fucosidase-treated 
samples; the open triangle represents baseline immunoreactivity of 
an aliquot  removed before the addition  of fucosidase. 
Discussion 
Previous studies (Schneider et al.,  1978;  Mintz et al.,  1981) 
have shown that gastrulation and  spicule-formation by sea 
urchin embryos both are inhibited by the N-linked glycopro- 
tein inhibitor tunicamycin. In addition, the incorporation of 
[3H]glucosamine into glycoconjugates and of 4sCa+2 into spic- 
ules are blocked in the presence of tunicamycin at concentra- 
tions that do not inhibit protein synthesis (Mintz et al., 1981). 
These earlier biochemical findings, coupled with morpho- 
logical evidence obtained using Concanavalin A-gold (Decker 
et al.,  1987), implicated a role for N-linked glycoproteins in 
skeleton formation by developing sea urchin embryos. These 
findings are consistent with those found during this study. In 
fact, our finding that mAb 1223,  which inhibits calcium up- 
take and spicule formation in vitro, is directed against a car- 
bohydrate epitope suggests that we have identified a key car- 
bohydrate structure that might participate in calcium uptake 
and skeleton formation by spicule forming PMCs. 
Primary mesenchyme cells have a unique task to accom- 
plish during a very short interval of embryonic development: 
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the confines of the embryonic blastocoel. The sea water sur- 
rounding the embryo is rich in calcium (",,10 raM); however 
the calcium concentration in the blastocoel has not been 
well-defined. Almost certainly, however, it is lower than that 
in sea water.  The strategy of the skeleton-forming embryo 
must be to import calcium from the sea water through the 
ectodermal cell layer and by some mechanism provide this 
calcium to the PMCs for uptake and conversion to CaCO3. 
The molecular mechanisms involved in this complex process 
are completely unknown. 
Several properties of the 1223 glycoprotein are of special 
interest. One is that this protein is extremely immunogenic 
when injected into mammalian cells. In fact, several labora- 
tories, including our own, have obtained antibodies to this 
protein merely by injecting mixed populations of dissociated 
cells from gastrula-stage embryos (Carson et al., 1985; An- 
strom et al., 1987) or intact spicule-forming cells (Shimizu 
et al., 1988). More interestingly, all of these antibodies have 
been shown to recognize carbohydrate epitopes (Anstrom et 
al., 1987; Shimizu et al., 1988;  and this report). A second 
is that the expression of the carbohydrate structures recog- 
nized by these antibodies at the cell surface of the PMCs is 
coordinated with the differentiated functions of these cells; 
i.e., calcium uptake and skeleton formation. In particular, 
the 1223 epitope is developmentally regulated, appearing on 
the surface of the PMC at the time that uptake of 45Ca÷2 in- 
creases (Farach et al., 1987). A third point of interest is that 
the 1223 glycoprotein binds calcium. More specifically, the 
oligosaccharide bearing the 1223 epitope binds calcium in 
vitro under conditions that may resemble  those  in  vivo. 
Whether this is related to its function remains a matter of 
speculation at present. Taken together, these findings strong- 
ly suggest that the 1223 glycoprotein plays a role in calcium 
uptake and skeleton formation by gastrula stage embryos of 
the sea urchin. We hypothesize that at least one function of 
the 1223 glycoprotein may be to facilitate the sequestration 
of calcium ions to the cell surface of the PMC such that they 
may be  subsequently  internalized  for deposition into the 
growing embryonic skeleton. 
The relationship of the 1223 epitope to calcium uptake is 
supported by other observations. In addition to the observa- 
tion that mAb 1223 inhibits calcium uptake by PMCs (Car- 
son et al., 1985), this monoclonal also alters the binding of 
Ca channel ligands to PMCs. Specifically, we found that in 
the presence of mAb  1223  (5  #g/ml),  the binding of di- 
hydropyridines to cultured PMCs  was  increased approxi- 
mately twofold whereas the binding of verapamil was de- 
creased to one-third of  control levels (Farach-Carson, M. C., 
and W. J. I~nnarz, unpublished observations). Unfortunate- 
ly, attempts to study PMCs electrophysiologically using the 
patch-clamp technique proved unsuccessful because of their 
small size and elaborate extracellular matrix. Of many other 
tissues and cell lines that were surveyed, only the nonfusing 
embryonic mouse myoblast cell line designated BC3H1  ex- 
pressed detectable amounts of the 1223 epitope (Caffrey and 
Farach, 1988). The relevance of these findings to the present 
study is that mAb 1223 also alters Ca  ÷2 uptake into BC3H1 
cells. More specifically, patch-clamp studies have shown that 
in BC3H1 cells, mAb 1223 interacts with the high threshold 
Ca channel protein. This evidence, coupled with the finding 
that rnAb 1223 alters binding of Ca channel ligands to PMCs, 
indicates that the 1223 oligosaccharide epitope may be either 
part of or intimately associated with the voltage-dependent 
Ca channel in both  spicule-forming cells  and embryonic 
myoblasts. 
In this study, we have partially characterized the epitope 
recognized by mAb 1223 on the 130-kD  glycoprotein. The 
epitope appears to be part of an anionic N-linked oligosac- 
charide chain on the core protein. In light of its ability to bind 
Ca  ÷2 ions, the finding that it bears a net negative charge is 
not surprising. On the other hand, several of  the observations 
that we made regarding the nature of the sugar moieties were 
initially surprising. A previous report (Anstrom et al., 1987) 
found that the 1223 epitope was not expressed by sea urchin 
embryos grown in sulfate-depleted sea water,  inferring that 
it might contain sulfated sugars.  To test this more directly, 
we labeled cultures of isolated spicule-forming cells or gas- 
trula-stage embryos with 35SO, and then isolated the 1223 
pronase glycopeptide using a mAb 1223 immunoaffinity  col- 
umn. No mAb 1223-immunoreactive, sulfate-labeled mate- 
rial was detected in either gastrulae or PMCs, although dot 
blot analysis of the immunoaffinity  purified material demon- 
strated that the 1223 epitope was present in both cases (data 
not shown). Thus we were unable to obtain direct evidence 
that the particular chain bearing the 1223 epitope is sulfated. 
Selective chemical and enzymatic degradations before im- 
munoblotting demonstrate that the  1223  epitope contains 
sialic acid residues that are likely to be O-acetylated. The re- 
sistance to periodate coupled with the susceptibility to neur- 
aminidase only after treatment with mild base indicates the 
most likely point of substitution to be at the 9 position, al- 
though additional substitutions could occur at the 7 or 8 posi- 
tions (see Cheresh et al., 1984; Varki and Diaz, 1984).  The 
elution position of the 1223 glycopeptide from DE 52 is con- 
sisent with a proposed structure containing multiple negative 
charges. Comparison with standard anionic oligosaccharides 
with defined numbers of negative charges indicate that there 
must be either greater than three sialic acid residues or other 
anionic charge groups (Swiedler et al., 1983; Beeley, 1985). 
Based upon results showing a partial susceptibility to degra- 
dation by neuraminidases,  including Endo N,  we  cannot 
eliminate the possibility that some polysialates may be pres- 
ent. Nonetheless, the complete susceptibility to neuramini- 
dase after brief exposure to alkali provides strong evidence 
that the 1223 glycopeptide contains sialic acid. Unfortunately, 
the only way that the behavior of  the 1223 glycopeptide could 
be monitored during anion exchange chromatography was 
with mAb  1223 binding. Since immunoreactivity was lost 
during enzyme digestion, we could not detect alterations in 
binding to DE 52 after neuraminidase digestion. 
The residue(s)  involved in calcium binding to the  1223 
glycopeptide have an apparent pK, value of 4.0-5.0.  Nega- 
tively charged oligosaccharide structures that might promote 
Ca  +2 binding with this pK~ include phosphate or carboxyl- 
containing structures. Depending upon the properties of the 
microenvironment including neighboring groups, any of a 
number of other charged moieties could function with this 
pK,. Sialic acid residues have been demonstrated to func- 
tion as calcium binding sites in other systems (Jaques et al., 
1977;  Kouvonen  and  Grasbeck,  1984).  Physicochemical 
measurements based upon chemical shifts in '3C and 'H nu- 
clear magnetic resonance spectra indicate that Ca  +2 binds to 
sialic acid in free solution as a 1:1 complex with an associa- 
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fate groups in heparin have also been shown to function as 
Ca  ÷z binding sites,  as have other sulfated glycosaminogly- 
cans  (Ayotte  and  Perlin,  1986;  Vannucchi  et  al.,  1978). 
Based upon earlier findings coupled with the results pre- 
sented here, we propose that at least one site of calcium bind- 
ing on the  130-kD  glycoprotein resides  on the  3,200-Mr 
oligosaccharide chain recognized by mAb 1223. However, 
because mAb 1223 does not inhibit calcium binding to the 
1223 pronase glycopeptide and because treatments that de- 
stroy immunoreactivity do not destroy Ca  +z binding activ- 
ity, it is unlikely that the sites of antibody binding and cal- 
cium binding are identical. 
Our observation that mAb  1223 binds with greater effi- 
ciency to the aggregated form of the 1223 glycopeptide (Fig. 
3) may indicate that mAb 1223 binds better to the calcium 
salt as compared to the free acid form of the epitope. The 
tendency of both the isolated 1223 glycopeptide (Fig. 3) and 
the intact glycoprotein (Fig. 6) to aggregate in solution is 
probably because of the formation of protein-calcium com- 
plexes that form stable aggregates. This type of behavior has 
been previously observed for other membrane proteins such 
as the asialoprotein receptor (for review,  see Ashwell and 
Harford, 1982). 
Understanding the structure of the 1223 oligosaccharide is 
complicated by our results following fucosidase treatment, 
where we found that immunoreactivity increased linearly 
with the time of digestion. This implies that removal of fu- 
cose residues from the 1223 oligosaccharide either increases 
binding affinity or exposes cryptic binding sites. The speci- 
ficity of this enzyme indicates that these residues would oc- 
cupy terminal positions (Carlsen and Pierce,  1972).  In this 
case, fucosylation of the oligosaccharide chain would lead to 
masking of the epitope recognized by mAb 1223. This type 
of"epitope masking" by fucose residues is well precedented 
in living cells. The blood group antigens, for example, were 
found to be frequently interconverted by the addition or re- 
moval of fucose residues (Feizi and Childs, 1985). It is even 
possible that the fucose residues occupy terminal positions 
as capping sugars after internal sialic acid moieties. This 
type of structure was reported to occur in the sea cucumber, 
in which fucopyranosyl-(1,4)-N-glycolylneuraminic  acid was 
identified (Van der Meer et al.,  1983).  The functional sig- 
nificance of the fucosylation of the 1223 glycoprotein is not 
clear at present. 
In spite of  the growing body of information  that is available 
concerning the variety of carbohydrate structures assembled 
by living cells, very little is known about the functions of the 
oligosaccharides themselves. With rare exception, such as 
the mannose-6-phosphate receptor recognition system for 
uptake and targeting of lysosomal proteins (Kaplan et al., 
1977; Ullrich et al., 1978; Fischer et al., 1980) or the asialo- 
glycoprotein receptor mechanism for removal of galactose- 
terminating glycoproteins from the circulation (see Ashwell 
and Harford, 1982),  the functions of most oligosaccharide 
structures remain unknown. Monoclonal antibodies directed 
against discrete carbohydrate epitopes on cell surface glyco- 
proteins have expanded our knowledge about the role of car- 
bohydrates in processes  such as fertilization, intercellular 
adhesion, tumorigenesis, and host-parasite interaction (for 
review, see Ivatt, 1984; Sharon, 1984; Feizi, 1985). It is also 
becoming apparent that negatively charged oligosaccharide 
structures might play a  role in binding of divalent cations 
such as calcium to the cell surface (Long and Mouat, 1971; 
Kouvonen and Grasbeck, 1984). Such a function might pro- 
vide a new direction for the exploration of structure-function 
relationships for carbohydrates. The results of  this study sup- 
port the notion that certain anionic oligosaccharides are in- 
volved in calcium sequestration to the cell surface of spicule- 
forming cells. Experiments are underway to further test this 
hypothesis and to elucidate the exact structure of the 1223 
oligosaccharide. 
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